A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Cerliponase alfa (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 12 May 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2022.
- 12 May 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2022.